Checkmate Pharmaceuticals Secures $85 Million in Series C Financing
Funding Supports Further Clinical Development of Checkmate Pharmaceuticals TLR9 Agonist, CMP-001, in Melanoma and other Oncology Indications June 10, 2020 07:00 AM Eastern Daylight Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Checkmate Pharmaceuticals (Checkmate), a clinical stage biotechnology company focused on improving patients’ lives with its novel approach to cancer immunotherapy, announced that it has completed an $85 million […]
